The study on comparison between Hytrin Single therapy and Hinechol and Hytrin combined therapy with Lower urinary tract symptom

The study on comparison between Hytrin Single therapy and Hinechol and Hytrin combined therapy on patients with Benign prostatic hyperplasia accompanied with Lower urinary Tract Symptom

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003670

Enrollment

130

Registered

2019-03-26

Start date

2019-04-30

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Hytrin (Terazosin) alone or Hytrin (Terazosin) and Hinechol (Bethanechol) are administrated on patients suffering from dysuria due to benign prostatic hyperplasia.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those with maximum flow rate (Qmax) is less than 15.0mL/s and postvoid residual urine is more than 50mL due to benign prostatic hyperplasia

Exclusion criteria

Exclusion criteria: 1) Those with complete spinal cord lesion 2) Those with complete urinary retention or with an indwelling catheter 3) Those with bladder outlet obstruction or prostatic cancer or who underwent prostatic surgery 4) Those with severe cardiovascular or hepatic disorder or orthostatic hypotension or severe renal dysfunction. 5) Those who are taking 5a-reductase inhibitor, cholinergics, anti-cholinergics, alpha antagonist or agonist, beta agonist 6) Those with asthma or Parkinson disease. 7) Those who are sensitive to cholinergics or alpha-blocker 8) Those who are judged to be improper for this clinical trial.

Design outcomes

Primary

Measure	Time frame
IPSS (International Prostate Symptom Score)	—

Secondary

Measure	Time frame
Average flow rate;Postvoid Residual Urine Volume	—

Countries

Korea, Republic of

Contacts

Public ContactJeong Woo Lee

Dongguk University Ilsan Hospital

jwleemed@hanmail.net+82-31-961-7456

Outcome results